Pharma Stocks

Torrent Pharma FDA inspection ends with clean chit; co hikes JB Chemicals stake to 48.75%

Torrent Pharmaceuticals Ltd on Friday (January 23) informed that the US Food and Drug Administration (FDA) inspected its Dahej manufacturing facility from January 19-23, 2026. The company said the inspection has been concluded with zero observations.

Also, Torrent Pharmaceuticals has increased its holding in JB Chemicals & Pharmaceuticals Ltd to 48.75% on a fully diluted basis following the acquisition of 37,82,566 equity shares, representing 2.36% of JB Chemicals’ equity share capital. The shares were purchased from certain employees of JB Chemicals in line with the share purchase agreement dated July 3, 2025.

Also Read: Torrent Pharma Q1 Result | Net profit rises 20% to ₹548 crore; revenue, margin improves

This acquisition forms part of Torrent Pharmaceuticals’ ongoing strategy to consolidate its stake in JB Chemicals, following earlier acquisitions and disclosures made between June-December 2025, as well as January 21, 2026. Post-acquisition, Torrent Pharmaceuticals now holds a total of 7.83 crore equity shares in JB Chemicals.

Second quarter results

Torrent Pharmaceuticals reported a strong set of earnings for the quarter ended September 2025 (Q2FY26), posting a 30.4% year-on-year increase in net profit to ₹591 crore, compared with ₹453 crore in the same period last year.

Revenue from operations rose 14.3% to ₹3,302 crore from ₹2,889 crore a year earlier, while EBITDA grew 15.3% to ₹1,083 crore, maintaining a healthy operating margin of 32.8%, slightly higher than 32.5% in the corresponding quarter of the previous year.

Also Read: CCI clears Torrent Pharma’s proposal to buy stake in JB Chemicals

The company’s India business, its largest contributor, delivered a healthy 12% growth to ₹1,820 crore, led by continued outperformance in focus therapies and strong momentum in the chronic portfolio, which grew 13% versus IPM growth of 11%.

Shares of Torrent Pharmaceuticals Ltd ended at ₹3,931.30, down by ₹92.70, or 2.30%, on the BSE.

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button